Review ArticleReview Article
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
James H. Revkin, Charles L. Shear, Hubert G. Pouleur, Steven W. Ryder and David G. Orloff
Pharmacological Reviews March 2007, 59 (1) 40-53; DOI: https://doi.org/10.1124/pr.59.1.1
James H. Revkin
Pfizer Global Research and Development, New London, Connecticut (J.H.R., C.L.S., H.G.P., S.W.R.); and Medpace Inc., Cincinnati, Ohio (D.G.O.)
Charles L. Shear
Pfizer Global Research and Development, New London, Connecticut (J.H.R., C.L.S., H.G.P., S.W.R.); and Medpace Inc., Cincinnati, Ohio (D.G.O.)
Hubert G. Pouleur
Pfizer Global Research and Development, New London, Connecticut (J.H.R., C.L.S., H.G.P., S.W.R.); and Medpace Inc., Cincinnati, Ohio (D.G.O.)
Steven W. Ryder
Pfizer Global Research and Development, New London, Connecticut (J.H.R., C.L.S., H.G.P., S.W.R.); and Medpace Inc., Cincinnati, Ohio (D.G.O.)
David G. Orloff
Pfizer Global Research and Development, New London, Connecticut (J.H.R., C.L.S., H.G.P., S.W.R.); and Medpace Inc., Cincinnati, Ohio (D.G.O.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
James H. Revkin, Charles L. Shear, Hubert G. Pouleur, Steven W. Ryder and David G. Orloff
Pharmacological Reviews March 1, 2007, 59 (1) 40-53; DOI: https://doi.org/10.1124/pr.59.1.1
Review ArticleReview Article
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
James H. Revkin, Charles L. Shear, Hubert G. Pouleur, Steven W. Ryder and David G. Orloff
Pharmacological Reviews March 1, 2007, 59 (1) 40-53; DOI: https://doi.org/10.1124/pr.59.1.1
Jump to section
- Article
- Abstract
- I. Introduction
- II. Definitions
- III. Validation of New Surrogate Markers
- IV. Correlation between Carotid Intima-Media Thickness, Intravascular Ultrasound, and Clinical Events
- V. Circulating Biomarkers
- VI. Surrogate Endpoints and Regulatory Approval
- VII. Future Prospects: Biomarkers and Surrogate Endpoints
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement